Skip to main content
TipRanks
Go Ultimate75% OFF

Cytosorbents (CTSO) AI Stock Analysis

492 Followers
CTSO

Cytosorbents

(NASDAQ:CTSO)

Select Model
Rating:49Neutral
Price Target:$5.50â–²(7.21% Upside)
Action:reiterated
Date:11/13/26

CTSO’s score is held back primarily by weak financial fundamentals—deep losses, negative TTM operating/free cash flow, and a stressed balance sheet with negative equity and meaningful debt. Partially offsetting this are improving operational trends discussed on the earnings call (gross margin expansion and near/breakeven operating cash flow) and mildly improving near-term technical momentum, while valuation remains constrained by ongoing unprofitability.

Positive Factors
Strong gross margins and improving cost efficiencyGross margin in the mid-70% range, together with lower cost of goods sold and production-process improvements, supports attractive product economics. If sustained, these gains can provide greater operating leverage as cartridge utilization grows and help the company progress toward durable profitability.
Negative Factors
Persistent losses and negative cash generationDespite improved quarterly results, the company remains substantially unprofitable and cash-flow negative on a trailing basis. Continued losses and cash consumption can constrain investment in commercial growth, increase dependence on financing, and make the path to self-funded expansion less certain.

Cytosorbents (CTSO) vs. SPDR S&P 500 ETF (SPY)

-100%-80%-60%-40%-20%0%20%CTSO-69.06%SPY+9.80%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$16.17M
Dividend Yield
―
Average Volume (3M)
36.93K
Price to Earnings (P/E)
-1.0
Beta (1Y)
0.99
Revenue Growth
9.04%
EPS Growth
-44.94%
Country
US
Employees
129
Sector
Healthcare
Sector Strength
51
Industry
Medical - Devices

Cytosorbents Business Overview & Revenue Model

Company Description

Cytosorbents Corporation specializes in creating and bringing to market innovative medical devices. Their core expertise lies in a unique blood purification platform, built upon a proprietary adsorbent and porous polymer technology. The company's lea...

How the Company Makes Money

CytoSorbents makes money primarily by selling its CytoSorb hemoadsorption cartridges and related consumables for use in hospitals, with revenue recognized when products are delivered/used according to customer contracts. The company’s key revenue str...

Cytosorbents Earnings Call Summary

Earnings Call Date:Nov 12, 2026(Q3-2026)|% Change Since:-4.47%|Next Earnings Date:May 14, 2025
Earnings Call SentimentPositive

The call was predominantly positive. The company achieved operating cash flow breakeven, substantially improved gross margin and adjusted EBITDA, reduced operating costs and cash usage, and reported progress in rebuilding commercial capacity and advancing DrugSorb-ATR and HemoDefend-BGA. The principal challenges were the approximately 20%-21% decline in Germany, a higher nine-month net loss caused by a non-cash foreign currency swing, the possibility of future quarters with modest cash burn, outstanding Nasdaq and debt-restructuring requirements, and uncertainty around regulatory approval and timing.

Positive Updates

Operating Cash Flow Breakeven Achieved
The company achieved its objective of reaching operating cash flow breakeven in the second half of 2026, generating approximately $43,000 of positive operating cash flow in the third quarter, excluding $251,000 of restructuring payments.

Negative Updates

German Sales Declined
Germany, representing 24% of third-quarter sales, declined approximately 20%-21% year-over-year. Management attributed the decline principally to reduced sales-force and territory coverage during restructuring.

Company Guidance

Management is targeting product gross margins consistently in the mid-70% range and expects to remain at or near operating cash flow break-even, while noting that break-even will not be a straight line, every quarter will not be positive, and some quarters may show a modest burn and others a modest positive cash flow; it is actively working to satisfy the remaining Nasdaq listing requirement and debt restructuring by the end of this year, plans to add another German sales representative next month and two more by early 2027, expects a new BRILINTA De Novo submission in early 2027 subject to necessary work and regulatory interactions with a decision by FDA 150 days later, expects a separate Eliquis and Xarelto submission in 2027, and estimates an initial U.S. and Canadian addressable market of approximately $300 million to start, potentially expanding to $1 billion- $2 billion.

Cytosorbents Financial Statement Overview

Summary

Despite strong and stable ~70%+ gross margins and a sharp TTM revenue rebound (~65%), CTSO remains deeply unprofitable (TTM net margin ~-49%) with ongoing operating losses. Cash flow is still negative in TTM (operating cash flow ~-6.8M; FCF ~-6.9M), and the balance sheet is pressured by negative equity (~-2.3M) alongside rising debt (~29.6M), increasing financing/dilution risk.

Income Statement

28Negative

Balance Sheet

18Very Negative

Cash Flow

22Negative
Financial statement breakdown
BreakdownTTMDec 2025Mar 2025Dec 2023Dec 2022Dec 2021
Income Statement
Total Revenue37.46M37.06M35.59M31.08M34.69M40.11M
Gross Profit27.31M26.49M24.89M21.95M20.73M29.06M
EBITDA-12.03M-4.36M-19.27M-27.88M-29.75M-24.17M
Net Income-16.88M-8.20M-20.72M-29.25M-32.81M-24.56M
Balance Sheet
Total Assets37.16M44.18M47.37M53.26M63.23M89.52M
Cash, Cash Equivalents and Short-Term Investments4.21M6.25M3.28M14.13M22.14M52.14M
Total Debt29.57M29.11M26.89M18.31M18.25M13.82M
Total Liabilities39.47M38.28M36.26M29.99M27.86M26.94M
Stockholders Equity-2.31M5.90M11.11M23.28M35.37M62.58M
Cash Flow
Free Cash Flow-8.12M-12.54M-14.71M-22.59M-34.69M-18.29M
Operating Cash Flow-8.00M-12.38M-14.43M-21.66M-28.23M-14.01M
Investing Cash Flow-380.00K-415.00K-669.43K-936.24K-6.46M-4.28M
Financing Cash Flow2.48M9.31M9.33M14.47M4.96M715.20K

Cytosorbents Technical Analysis

Technical Analysis SentimentPositive
Last Price5.13

Price Trends

50DMA4.75Positive
100DMA6.04Negative
200DMA8.90Negative

Market Momentum

MACD0.11Negative
RSI51.89Neutral
STOCH46.20Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CTSO, the sentiment is Positive. The current price of 5.13 is above the 20-day moving average (MA) of 4.93, above the 50-day MA of 4.75, and below the 200-day MA of 8.90, indicating a neutral trend. The MACD of 0.11 indicates Negative momentum. The RSI at 51.89 is Neutral, neither overbought nor oversold. The STOCH value of 46.20 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for CTSO.

Cytosorbents Risk Analysis

Cytosorbents disclosed 39 risk factors in its most recent earnings report. Cytosorbents reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

0 New Risks

Cytosorbents Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

CTSO against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
CTSOCTSO49Neutral$16.17M-0.96-1339.98%―9.04%-44.94%
TELATELA44Neutral$32.84M-0.98425.91%―1.46%15.79%
BDMDBDMD42Neutral$5.82M-0.19-48.23%―――
ECORECOR42Neutral$44.75M-3.39498.83%―27.26%20.47%
ICCMICCM42Neutral$5.55M-0.19-180.46%―31.80%27.37%
MDAIMDAI41Neutral$42.16M-3.98100.93%―-38.62%55.03%

* Healthcare Sector Average

Performance Comparison

0%100%CTSOECORTELAMDAIICCMBDMDDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
CTSO and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
CTSOCytosorbents Corp5.13-9.00-63.70%
ECORElectrocore4.850.142.97%
TELATela Bio, Inc.0.73-0.44-37.95%
MDAISpectral Ai, Inc. Class A1.31-0.12-8.39%
ICCMIcecure Medical Ltd.1.00-18.80-94.96%
BDMDBaird Medical Investment Holdings Ltd0.10-1.31-92.70%

Cytosorbents Corporate Events

Business Operations and StrategyDelistings and Listing ChangesRegulatory Filings and Compliance

CytoSorbents Regains Nasdaq Compliance, Pursues Growth Initiatives

Positive
Sep 23, 2026

On September 22, 2026, CytoSorbents regained compliance with Nasdaq’s minimum bid price rule after its shares closed at or above $1.00 for 10 consecutive trading sessions, leading Nasdaq to close the matter the following day. The company remains out...

Delistings and Listing ChangesRegulatory Filings and ComplianceShareholder MeetingsStock Split

CytoSorbents Announces One-for-Twenty Reverse Stock Split

Neutral
Sep 8, 2026

On September 3, 2026, CytoSorbents announced that it would implement a one-for-twenty reverse stock split of its common stock, following shareholder approval at its August 13, 2026 annual meeting. The company filed an amendment to its certificate of...

Executive/Board ChangesShareholder MeetingsStock Split

CytoSorbents Shareholders Approve Governance Measures and Reverse Split

Positive
Aug 14, 2026

CytoSorbents Corporation held its 2026 Annual Meeting of Stockholders on August 13, 2026, with a quorum of 42,487,327 shares represented out of 62,842,748 outstanding. Stockholders elected five directors to serve until the 2027 meeting and approved,...

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 13, 2026